Login / Signup

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.

Nikhita Kathuria-PrakashLidia P LopezSteven RamanHuihui YeJordan AnaokarAnthony SiskAllan J PantuckAlexandra Drakaki
Published in: JCO precision oncology (2024)
ALK-rearranged RCC refractory to several lines of treatment has a durable response when treated with alectinib.
Keyphrases
  • advanced non small cell lung cancer
  • metastatic renal cell carcinoma
  • epidermal growth factor receptor
  • renal cell carcinoma
  • replacement therapy
  • newly diagnosed
  • tyrosine kinase